Heading into today’s session biotech giant Biogen had closed in the red every day this month. This morning’s weakness appeared to be a continuation after shares opened with a downside gap. At mid day BIIB appears to have found its footing after dipping into a major support zone. After the recent bearish action patient BIIB investors should begin to take a more positive view of the stock.
